A Study of ARQ 197 in Combination With Erlotinib
NCT01069757
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-small-cell Lung Cancer
Interventions
DRUG:
ARQ 197 and Erlotinib
Sponsor
Kyowa Kirin Co., Ltd.